Malignant Laryngeal Neoplasm

Diseases /

Back to Diseases List

Associated Genetic Biomarkers

ABL1
ABL1 Amplification
ABL1 Fusion
ABL1 Mutation
BRAF
BRAF Amplification
BRAF Mutation
DDR2
DDR2 Amplification
DDR2 Mutation
EGFR
EGFR Amplification
EGFR Mutation
EPHA2
EPHA2 Amplification
EPHA2 Mutation
ERBB2
ERBB2 Amplification
ERBB2 Mutation
ERBB4

ERBB4 Amplification
ERBB4 Loss
ERBB4 Mutation
FGFR1
FGFR1 Amplification
FGFR1 Fusion
FGFR1 Mutation
FGFR2
FGFR2 Amplification
FGFR2 Fusion

FGFR2 Mutation
FLT1
FLT1 Amplification
FLT1 Mutation
FLT4
FLT4 Amplification
FLT4 Mutation
FRK
FRK Mutation
KDR

KDR Amplification
KDR Mutation
KIT
KIT Amplification
KIT Fusion
KIT Mutation
MAPK11
MAPK11 Amplification
MAPK11 Mutation
PDGFRA

PDGFRA Amplification
PDGFRA Fusion
PDGFRA Mutation
PDGFRB
PDGFRB Amplification
PDGFRB Fusion
PDGFRB Mutation
RAF1
RAF1 Amplification
RAF1 Mutation

RET
RET Amplification
RET Fusion
RET Mutation
TEK
TEK Mutation
TRNAK2
TRNAK2 Mutation
VEGFA
VEGFA Amplification

VEGFB
VEGFB Amplification
VEGFC
VEGFC Amplification

Overview

NCI Definition: A primary or metastatic malignant neoplasm involving the larynx. The majority are carcinomas. [1]

Malignant laryngeal neoplasms most frequently harbor alterations in TP53, CDKN2A, PIK3CA, KMT2D, and CCND1 [2].

Most Commonly Altered Genes in Malignant Laryngeal Neoplasm

TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, PIK3CA Mutation, and TP53 Exon 5 Mutation are the most common alterations in malignant laryngeal neoplasm [2].

Top Alterations in Malignant Laryngeal Neoplasm

Clinical Trials

View Clinical Trials for Malignant Laryngeal Neoplasm

There is 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are completed or closed. Of the trial that contains malignant laryngeal neoplasm as an inclusion criterion, 1 is phase 2 (1 open).

ABL1, BRAF, and DDR2 are the most frequent gene inclusion criteria for malignant laryngeal neoplasm clinical trials [3].

Trials Investigating Malignant Laryngeal Neoplasm by Gene and Recruiting Status

Afatinib, cabozantinib, and regorafenib are the most common interventions in malignant laryngeal neoplasm clinical trials.

Drugs Being Investigated in Malignant Laryngeal Neoplasm Trials by Recruiting Status

Significant Genes in Malignant Laryngeal Neoplasm

ABL1 +

ABL1 is altered in 2.67% of malignant laryngeal neoplasm patients [2].

ABL1 is an inclusion eligibility criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF +

BRAF is an inclusion eligibility criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

DDR2 +

DDR2 is an inclusion eligibility criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains DDR2 status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR +

EGFR is altered in 12.94% of malignant laryngeal neoplasm patients [2].

EGFR is an inclusion eligibility criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

EPHA2 +

EPHA2 is an inclusion eligibility criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 +

ERBB2 is altered in 2.35% of malignant laryngeal neoplasm patients [2].

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB4 +

ERBB4 is altered in 2.44% of malignant laryngeal neoplasm patients [2].

ERBB4 is an inclusion eligibility criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB4 status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR1 +

FGFR1 is altered in 2.47% of malignant laryngeal neoplasm patients [2].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR2 +

FGFR2 is altered in 2.47% of malignant laryngeal neoplasm patients [2].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT1 +

FLT1 is altered in 5.71% of malignant laryngeal neoplasm patients [2].

FLT1 is an inclusion eligibility criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT4 +

FLT4 is altered in 3.03% of malignant laryngeal neoplasm patients [2].

FLT4 is an inclusion eligibility criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FRK +

FRK is an inclusion eligibility criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FRK status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

KDR +

KDR is altered in 2.47% of malignant laryngeal neoplasm patients [2].

KDR is an inclusion eligibility criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KDR status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT +

KIT is altered in 2.35% of malignant laryngeal neoplasm patients [2].

KIT is an inclusion eligibility criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KIT status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

MAPK11 +

MAPK11 is an inclusion eligibility criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MAPK11 status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA +

PDGFRA is altered in 1.19% of malignant laryngeal neoplasm patients [2].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRB +

PDGFRB is altered in 1.43% of malignant laryngeal neoplasm patients [2].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

RAF1 +

RAF1 is altered in 1.43% of malignant laryngeal neoplasm patients [2].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

RET +

RET is altered in 3.53% of malignant laryngeal neoplasm patients [2].

RET is an inclusion eligibility criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RET status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

TEK +

TEK is an inclusion eligibility criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TEK status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

TRNAK2 +

TRNAK2 is an inclusion eligibility criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TRNAK2 status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFA +

VEGFA is altered in 2.22% of malignant laryngeal neoplasm patients [2].

VEGFA is an inclusion eligibility criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains VEGFA status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFB +

VEGFB is an inclusion eligibility criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFC +

VEGFC is an inclusion eligibility criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains VEGFC status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

Disease Details

Synonyms

Malignant Neoplasm of Larynx, Malignant Larynx Neoplasm, Malignant Laryngeal Tumor, Malignant Larynx Tumor, Malignant Tumor of the Larynx, Malignant Tumor of Larynx, Malignant Neoplasm of the Larynx

Parent(s)

Malignant Head and Neck Neoplasm

Children

Laryngeal Carcinoma, Malignant Supraglottis Neoplasm, Malignant Subglottic Neoplasm, Laryngeal Sarcoma, and Malignant Glottis Neoplasm

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Malignant Laryngeal Neoplasm

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in Malignant Laryngeal Neoplasm

Disease Details

References

About

Molecular Medicine

Content Types